Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients

Kidney and Blood Pressure Research

Volumn 37, Issue 4-5, 2013, Pages 259-268

  Choi, Ji Young ^a   Yang, Chul Woo ^b   Kim, Yeong Hoon ^c   Joo, Kwon Wook ^d   Yoo, Tae Hyun ^e   Lee, Kang Wook ^f   Lee, Sang Ho ^g   Moon, Ju Young ^g   Shin, Sug Kyun ^h   Huh, Wooseong ⁱ   Kim, Nam Ho ^j   Park, Sun Hee ^a   Kim, Chan Duck ^a   Kim, Yong Lim ^a  

^a Kyungpook National University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Inje University   (South Korea)

^d Seoul National University   (South Korea)

^e Yonsei University   (South Korea)

^f Chungnam National University   (South Korea)

^g Kyung Hee University Hospital   (South Korea)

^h Department of Internal Medicine National Health Insurance Corporation Ilsan Hospital ^*  (South Korea)

ⁱ Sungkyunkwan University   (South Korea)

^j Chonnam National University Medical School   (South Korea)

more..

Author keywords

Biomarker; Chronic kidney disease; Erythropoietin; Hemoglobin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FERROUS SULFATE; HEMOGLOBIN; IRON SACCHARATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PADGEM PROTEIN; PROHEPCIDIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BRAIN INFARCTION; CHRONIC KIDNEY DISEASE; DECREASED APPETITE; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEADACHE; HEMODIALYSIS; HUMAN; HYPERTENSION; IRON METABOLISM; IRON THERAPY; ISCHEMIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RHINOPHARYNGITIS; SEPSIS; UPPER RESPIRATORY TRACT INFECTION;

DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HALF-LIFE; HEMOGLOBINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84890338569     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000350151     Document Type: Article

References (23)

1. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000; 15: 1425-1430
2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
3. Minutolo R, Zamboli P, Chiodini P, Mascia S, Vitiello S, Stanzione G, Bertino V, Conte G, De Nicola L. Conversion of darbepoetin to low doses of cera maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif 2010; 30: 186-194
4. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (maxima). Lancet 2007; 370: 1415-1421
5. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC, Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U, Dougherty FC. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. Nephrol Dial Transplant 2010; 25: 4009-4017
6. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U. Once-monthly subcutaneous c.E.R.A. Maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2: 637-646
7. Topf JM. Cera: Third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008; 9: 839-849
8. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-2989
9. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-1343
10. Ziakka S, Zagorianakos A, Koutsovasili A, Kaperonis N, Poulikakos D, Sgantzos A, Kolovos V, Ntatsis G, Papagalanis N. Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis. Ren Fail 2011; 33: 923-928
11. Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998; 92: 4446-4452
12. Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sicklecell anaemia? Lancet 1998; 352: 566-567
13. Frijns CJ, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke 1997; 28: 2214-2218
14. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma p-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994; 83: 1535-1541
15. Huraib S, Gader AM, al-Momen AK, Abu-Aisha H, al-Wakeel J, Memon NA. One-year experience of very low doses of subcutaneous erythropoietin in continuous ambulatory peritoneal dialysis and its effect on haemostasis. Haemostasis 1995; 25: 299-304
16. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-Atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010; 33: 1529-1535
17. Heinisch BB, Vcelar B, Kapiotis S, Blann A, Wolzt M, Siller-Matula JM, Jilma B. The effect of erythropoietin on platelet and endothelial activation markers: A prospective trial in healthy volunteers. Platelets 2012; 23: 352-358
18. Kahraman S, Yilmaz R, Kirkpantur A, Genctoy G, Arici M, Altun B, Erdem Y, Yasavul U, Turgan C. Impact of rhuepo therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton) 2005; 10: 264-269
19. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic nondialysis chronic kidney disease patients. Nephron Clin Pract 2008; 110: c244-250
20. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: Regulation of mammalian iron metabolism. Cell 2010; 142: 24-38
21. Costa E, Pereira BJ, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Role of prohepcidin, inflammatory markers and iron status in resistance to rhepo therapy in hemodialysis patients. Am J Nephrol 2008; 28: 677-683
22. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis. Am J Hematol 2006; 81: 832-837
23. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004; 42: 387-389